Trending Aesthetic Treatments: What Patients Are Asking For

Non-invasive skin tightening has crossed a threshold. Cynosure Lutronic's XERF (monopolar radiofrequency) is accelerating adoption globally, marketed as 3x faster than prior RF platforms, with practices in North America and Europe now offering it as a core service. The clinical driver: patients want visible lift and texture improvement without downtime, and monopolar RF delivers measurable collagen remodeling at depth without ablation. Demand is particularly strong in the 40–65 demographic seeking an alternative to injectables for jowls and neck laxity. Equipment cost is substantial (typically $150K–$250K installed), but per-treatment margins are strong (gross margin 60–75% on $400–$800 treatments). If your practice lacks a skin-tightening modality, this is a category worth evaluating—but only if you have the capital and patient volume to support it. Lease-to-own and revenue-share models are available from manufacturers. Check with your device rep on break-even patient volume for your market.

The neck is no longer an afterthought. Allergan Aesthetics received FDA approval for Skinvive by Juvederm (hyaluronic acid injectable gel) specifically for neck lines and skin quality improvement—a new indication that signals market validation for treating the neck as a standalone aesthetic zone. Simultaneously, practitioners are using established biostimulators (PLLA, CaHA) off-label for neck volume and collagen induction. Patient demand for neck treatment has risen sharply, driven partly by video conferencing and selfie culture. Clinically, the neck is challenging: thin skin, high mobility, and risk of Tyndall effect or overcorrection. Skinvive's approval gives you a labeled option; biostimulators offer collagen-building benefits over time. Inventory cost is modest (syringes at standard filler pricing), but training and injection technique are critical. Consider bundling neck treatment with lower-face or jawline work to improve case economics and patient satisfaction.

The neuromodulator market is fragmenting. Galderma's Relabotulinumtoxin (Daxxify competitor) is in FDA regulatory review, and Evolus continues to market Jeuveau as a lower-cost alternative to Botox. Medicare price negotiation has also begun for Botox, signaling downward pricing pressure industry-wide. For practice owners, this means: (1) loyalty rebates and volume discounts are becoming more aggressive (Alle, Aspire, Evolus Rewards programs all offer tiered incentives); (2) patient acquisition cost for neuromodulator-only visits may rise as price competition intensifies; (3) longer-acting products (if approved) could reduce visit frequency and per-patient revenue. The strategic play is to deepen your neuromodulator offering with complementary treatments (filler, skin tightening, energy devices) to increase case value and reduce price sensitivity. Do not rely on neuromodulator volume alone.

Galderma's FDA approval of Restylane Contour for temple hollowing, and prior clearance of RHA Dynamic Volume for midface augmentation, reflect a trend: fillers are being repositioned as volumizers for specific anatomic zones, not just wrinkle-fillers. Temple hollowing is a common complaint in aging patients (loss of fat pad and bone resorption), and having a labeled filler option reduces liability and improves patient confidence. Midface volume loss is similarly high-demand. These indications expand your filler menu without new products—just new clinical applications. Inventory is standard (syringes at cost), but patient education is essential: many patients conflate temple hollowing with other concerns (brow ptosis, lateral orbital fat loss) and need clear consultation frameworks. Bundle temple and midface work with lower-face filler or neuromodulator to improve case economics.

The RF and energy-device market is consolidating. Steel Partners' acquisition interest in InMode (pending) signals PE appetite for consolidation in the aesthetic-device space. Cynosure Lutronic's XERF expansion and InMode's Morpheus platform are both gaining market share. For practice owners, this matters: (1) device manufacturers may change support, pricing, or warranty terms post-acquisition; (2) newer platforms (XERF, next-gen RF microneedling) are gaining adoption faster than legacy devices; (3) leasing and trade-in programs are becoming more flexible as manufacturers compete for installed base. If you are evaluating a device purchase, lock in pricing and support terms before any acquisition closes. Avoid being locked into a single manufacturer's ecosystem; prioritize platforms with strong clinical data and broad market adoption.

Before adding a trending treatment, ask: (1) Clinical demand: Are patients asking for it, or are you chasing hype? Survey your patient base and review your consultation notes for unsatisfied requests. (2) Competitive landscape: Are competitors in your market already offering it? If yes, what is their pricing and patient satisfaction? (3) Capital and training: What is the true cost (equipment, inventory, staff training, certification)? What is the break-even patient volume per month? (4) Margin and case value: Does it increase average case value or reduce price sensitivity? Skin-tightening and biostimulators typically improve case economics; neuromodulator-only trends do not. (5) Regulatory and liability: Is the treatment FDA-cleared or off-label? Do you have malpractice coverage? (6) Longevity: Is this a durable category (like injectables and skin tightening) or a temporary trend (like a specific brand or influencer-driven fad)? Prioritize treatments that solve real anatomic problems and improve patient outcomes, not treatments that depend on social-media momentum.